GC
CATX icon

Guggenheim Capital’s Perspective Therapeutics CATX Stock Holding History

Guggenheim Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,018
Closed -$14K – 2997
2015
Q3 		$14K Buy
+1,018
New +$14.7K ﹤0.01% 2914
2014
Q4 		– Sell
-1,010
Closed -$17K – 3020
2014
Q3 		$17K Sell
1,010
-2,352
-70% -$58.2K ﹤0.01% 2969
2014
Q2 		$105K Sell
3,362
-336
-9% -$8.43K ﹤0.01% 3002
2014
Q1 		$81K Buy
3,698
+841
+29% +$8.56K ﹤0.01% 3057
2013
Q4 		$14K Buy
2,857
+169
+6% +$890 ﹤0.01% 3153
2013
Q3 		$17K Hold
2,688
– – ﹤0.01% 3027
2013
Q2 		$13K Buy
+2,688
New +$14.5K ﹤0.01% 3006

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Guggenheim Capital's CATX Position: Q4 2015 in Review

Guggenheim Capital sold out of Perspective Therapeutics (CATX) in Q4 2015, closing a stake of 1,018 shares — an estimated $14K sold.

Guggenheim Capital first reported a position in CATX in Q2 2013 and held it in 7 quarters. The position peaked at $105K in Q2 2014. 26 funds tracked by Wall St. Rank hold CATX as of Q4 2015.

  • Guggenheim Capital reported no remaining Perspective Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Guggenheim Capital sold 1,018 Perspective Therapeutics shares in Q4 2015, an estimated $14K.
  • Guggenheim Capital first reported a position in Perspective Therapeutics in Q2 2013 and held it in 7 quarters.
  • Guggenheim Capital's Perspective Therapeutics position peaked at $105K in Q2 2014.
  • 26 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2015.

Based on Guggenheim Capital's 13F filing for Q4 2015, filed 16 Feb 2016.